This protocol applies to psoriasis presenting as limited disease — a presentation where disease extent supports a targeted topical approach rather than systemic intervention.
For limited psoriasis, first-line management centres on topical therapy. Specific agents drawn from established topical classes are used, providing effective disease control while avoiding systemic exposure. The complete regimen — including agent selection and clinical guidance — is available in the full protocol.
DOI: 10.1016/j.jaad.2020.02.044
In the treatment of psoriasis, topical therapies, such as vitamin D analogues and corticosteroids, may be effective and sufficient for managing limited disease and offer the additional benefit of fewer significant adverse effects due to the lack of systemic exposure.
View source ↗